Clinical Trials Logo

Diabetic Gastroparesis clinical trials

View clinical trials related to Diabetic Gastroparesis.

Filter by:

NCT ID: NCT04303195 Completed - Clinical trials for Diabetic Gastroparesis

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.

NCT ID: NCT04254549 Recruiting - Crohn Disease Clinical Trials

Rifaximin in Patients With Diabetic Gastroparesis

Start date: June 14, 2019
Phase: Phase 2
Study type: Interventional

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

NCT ID: NCT04208698 Terminated - Clinical trials for Diabetic Gastroparesis

A Scintigraphy Study in Adults With Diabetic Gastroparesis

Start date: February 17, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

NCT ID: NCT04028492 Recruiting - Gastroparesis Clinical Trials

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Start date: August 20, 2019
Phase: Phase 3
Study type: Interventional

To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

NCT ID: NCT03900325 Active, not recruiting - Clinical trials for Diabetic Gastroparesis

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics, and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.

NCT ID: NCT03680859 Completed - Gastroparesis Clinical Trials

Gastroparesis Registry 3

GpR3
Start date: January 24, 2019
Phase:
Study type: Observational

The purpose of this study is to create a new registry of patients with gastroparesis in order to better understand the characteristics of patients with gastroparesis and follow how their condition changes over time. The data collected may improve the understanding of the condition to enable better diagnosis and treatment.

NCT ID: NCT03544229 Completed - Clinical trials for Diabetic Gastroparesis

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Start date: October 14, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.

NCT ID: NCT03376399 Withdrawn - Weight Loss Clinical Trials

Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms

Start date: October 25, 2017
Phase:
Study type: Observational

The purpose of this registry is to evaluate if sleeve gastrectomy surgery will help with symptoms of delayed gastric emptying for patients suffering from diabetic gastroparesis.

NCT ID: NCT03342157 Terminated - Clinical trials for Diabetic Gastroparesis

Docusate/Senna for the Treatment of Diabetic Gastroparesis

Start date: April 2, 2018
Phase: Phase 2
Study type: Interventional

The aim of the study is to evaluate the efficacy of the stimulant laxative Senokot-S® for the treatment of diabetic gastroparesis. Senokot-S, and its metabolites, are thought to produce peristalsis, drive intraluminal fluid and electrolyte shifts, and have an irritant effect on the gut mucosa. These complex physiologic mechanisms appear may sufficiently promote stomach emp-tying, and thereby reduce or eliminate the severity of gastroparesis symptoms. In this open label study, participants will be randomized into high and low dose groups to assess for ideal dosing and tolerability. It is the overall goal of this study to select the most promising dose-strength for the treatment of mild through severe gastroparesis.

NCT ID: NCT03281577 Completed - Clinical trials for Diabetic Gastroparesis

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

Start date: January 2, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.